You are here

  • Home
  • Archive
  • Volume 10, Issue 1
  • Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study

 

Online download statistics by month:

Online download statistics by month: January 2022 to August 2025

AbstractFullPdf
Jan 2022572579185
Feb 2022424426136
Mar 202222422887
Apr 202221622499
May 202227728891
Jun 202217117959
Jul 202221522476
Aug 202218518963
Sep 202223924478
Oct 2022175179104
Nov 202214414471
Dec 202214214247
Jan 202315415451
Feb 202318918965
Mar 202312112459
Apr 202312312845
May 202313413436
Jun 202311711850
Jul 20239910037
Aug 202312612629
Sep 2023787831
Oct 2023878852
Nov 2023959543
Dec 2023798040
Jan 2024646446
Feb 202410110148
Mar 2024125126110
Apr 2024868849
May 202411511562
Jun 2024919051
Jul 202410310442
Aug 2024838137
Sep 2024777941
Oct 202411411449
Nov 2024888952
Dec 202411311569
Jan 202511311645
Feb 202520720751
Mar 202511811879
Apr 202512012160
May 202510110273
Jun 2025595942
Jul 2025220
Aug 2025110
Total626763522640